Introduction
Glioblastoma multiforme (GBM) represents one-fourth of all intracranial gliomas. It affects 5000 Americans and 1000 Italians per year, with a uniform and profound morbidity. Because of its morbidity it contributes to the cost of cancer on a pro capite basis more than any other tumour. Despite surgery, radiotherapy and/or chemotherapy, the prognosis is extremely poor with death resulting in 80% of patients from tumour recurrence within 6-12 months. This feature, unfortunately, has not substantially changed over the past 20 years, since glioblastoma invariably relapses within a few months of treatment. Tumour cell proliferation in the context of a completely post-mitotic tissue, in an anatomical compartment that is well separated from the rest of the body, makes GBM a good candidate for gene therapy by means of retroviral vectors. Gene therapy of brain tumours in human patients by intra-tumoural injection of retroviral vector producing cells (RVPC) was initiated in 1993 and is still ongoing. 1 The gene being transferred is the herpes simplex thymidine kinase (HSVtk) gene, which confers sensitivity to the anti-herpes drug ganciclovir (GCV). 2, 3 This treatment has proved free of toxicity and safe with no evidence of systemic spread of the retroviral vector. 4 However, clinical benefit was limited to small tumours (1.5 ml), possibly because only glioma cells immediately adjacent to the producer cells were transduced. An extended mode of therapeutic gene expression is needed for effective gene therapy of brain tumours. For this purpose, we devised a strategy that combines two different treatment modalities such as the simultaneous, retrovirus-mediated expression of suicide (cytotoxic) and immunomodulatory genes in an attempt to amplify the antitumour response. The effect of this therapeutic gene combination was assessed for the first time in four GBM patients. Figure 1 shows a schematic representation of the pLIL-2-TK vector used in the study. 
Results

Figure 1 Structure of the pLIL-2-TK retroviral vector. The pLIL-2-TK vector expresses the human interleukin 2 (IL-2) and the HSV thymidine kinase (tk) genes via a cap-dependent and an internal
Clinical features of GBM patients and response to combined TK-IL-2 treatment in vivo
The salient clinical features of the four treated patients suffering from relapsing GBM are presented in Table 1 . All patients underwent standard treatment including microsurgical bulk removal and conventional-fractionated or stereotactic-interstitial radiotherapy. One patient (patient 4) also had chemotherapy plus radioimmunotherapy. Patient 2 underwent surgery twice, and was treated by gene therapy (GT) for a second relapse. Tumour masses were larger than 3 cm in diameter (Ͼ120 ml) in patients 1 and 2, and larger than 2 cm in diameter (31 ml) in patients 3 and 4. Karnofsky performance status ranged from 70 to 90. 5 All patients underwent multiple computerised tomography (CT) and magnetic resonance imaging (MRI)-guided stereotactic injections of 1.5-3 × 10 8 RVPC in 2-6 ml fluid volume, except for patient 4 who was injected via an indwelling catheter positioned in the surgical cavity. A stereotactic biopsy was taken from patients 2 and 3, before GCV administration, to ascertain occurrence of tumour transduction. Results indicated safety of the treatment. Blood, urine and stool specimens were negative for the presence of replication-competent retrovirus (RCR). No adverse effect was noticed except for a slight, temporary increase in liver transaminases in patient 2 during GCV administration. This finding, however, did not lead to therapy discontinuation. Lymphocyte counts did not vary significantly after RVPC injection, before GCV treatment. By contrast, a decrease of lymphocyte counts was noticeable in all patients after GCV treatment was started, a likely sign of toxicity arising from GCV and dexamethasone, the latter drug being provided to prevent oedema. 1 The effect of treatment was evident by areas (2 ml) of tumour necrosis around injection sites (patients 1 and 2) or by a decreased tumour volume (up to 40 ml in patient 3) that consisted of about 50% of the original mass (Table 1 and Figure 2 ). It is noteworthy that tumour shrinkage in patient 3 continued after completion of therapy. Patients 1 and 2 died of tumour growth at 5 and 12 months after cessation of the GT regimen. Patient 3 died of pulmonary embolism 11 months after treatment while still in partial remission. Patient 4 is alive 11 months after treatment with apparently stabilised disease. The important response observed at MRI in patient 3 was also substantiated by a significant, long-standing clinical remission of hemiparesis.
Evaluation of in vivo gene transfer As for occurrence of gene transfer in vivo, results obtained with polymerase chain reaction (PCR) indicated that proviral sequences of the recombinant retrovirus were present within the tumour of both patients 2 and 3 ( Figure 3 ). In the case of patient 3 it cannot be excluded that the signal derived from RVPC, since a region of the gag gene not present in the vector was amplified together with the neo transgene (Figure 3a) . To investigate further whether transduction was accompanied by a state of active expression of the therapeutic genes, reverse transcriptase (RT)-PCR and in situ hybridisation were performed on biopsied materials using tk and neo primers and a tk RNA probe. Positive amplification signals for tk and neo transcripts were obtained only in patient 2 ( Figure 3a and 3b). Since gag transcripts were not revealed, this activity can only be related to vector-transduced cells and not to inoculated, actively transcribing RVPC. In situ hybridisation for tk mRNA was positive in endothelial cells ( Figure 4g ) and in scattered cells within the tumour (Figure 4e ).
Intratumour immuno-inflammatory reaction following genetic treatment
Immunohistochemical analysis of stereotactic biopsies showed an intense cellular infiltration in tumours from both patients (patients 2 and 3). patient 3 and Figure 4d , patient 2) along with rare NK cells and polymorphonucleated cells. In a biopsy of patient 2, where a necrotic area was surrounded by relatively conserved neural tissue and a degenerating tumour mass expressing glial fibrillary acidic protein (GFAP) in variable amounts, lymphocytes and macrophages were about equal in number, the lymphocytes being numerous in the conserved neural tissue and the macrophages in the degenerating tissue. Eighty percent of the CD3 + T lymphocytes were CD8 − , suggesting their 'helper/ inducer' phenotype, whereas the remaining 20% were cytotoxic CD8 + cells, mostly expressing the activated phenotype defined by strong granular immunostaining with a granzyme-B specific antibody. Forty percent of the CD68 + macrophages were young/activated macrophages as defined by their strong expression of Mac387 + calgranulins. 6 The biopsies of patient 3 fell in areas of necrotic degeneration and were less instructive. The majority of the cells were either macrophages or polymorphonucleated cells. No trace of RVPC was found by immunoperoxidase staining with an anti-mouse antibody in any specimen collected from patients.
Although no evidence for RCR was obtained in body fluids or tissues of any of the treated patients, one of them had circulating mononuclear cells positive for vector sequences (Figure 3c ). The PCR signal decreased following GCV treatment to rise again to the original level after GCV discontinuation (Figure 3c ). This seems to indicate that not all transduced peripheral blood leukocytes actively transcribed the transgenes during GCV treatment. For retroviral transduction these cells had to be in an active phase of proliferation, a condition likely encountered in vivo within the neoplastic lesion following IL-2 and antigen stimulation.
Intracerebral IL-2 production Sequential levels of IL-2 could be assessed in the cerebral spinal fluid (CSF) of patient 2 only, due to surgical reasons. In fact, only in patient 2 was a cystic cavity compartment present in the proximity of the tumour (a remnant of the primary tumour dissection) that was easily accessible during stereotactic procedures and was filled with CSF. Whereas no IL-2 was detected before RVPC inoculation, 8.5 IL-2 U/ml and 2.8 IL-2 U/ml were measured at 10 days after inoculation (before GCV treatment) and at 46 days after inoculation (after completion of GCV treatment), respectively.
Discussion
This article reports the first attempt in humans to combine the most promising strategies of cancer GT, ie enzyme-directed prodrug activation (tumour suicide) and cytokine-promoted tumour rejection. This combination has been suggested by recent experiments in animals 7 as promoting a synergistic effect. Our attempt was guided by the use of a single vector simultaneously expressing HSVtk and IL-2 as therapeutic genes. 8 The study was purposely designed to ascertain the efficacy and biological effects of tumour cell transduction. This evaluation was accomplished by taking stereotactic biopsies at a predetermined distance from the site of the RVPC injection, before GCV administration and tumourinduced suicide.
A number of features characterise the present study. No adverse reaction was noticed in any of the treated patients, ruling out the potential systemic toxicity of IL-2 9 and TK-GCV treatment. No evidence of RCR was obtained in any of the samples recovered from the four treated patients, confirming recent data on the safety of retrovirally mediated GT of brains tumours. 4 Transduction of circulating peripheral blood mononuclear cells was observed in one subject. Since these cells harbour a suicide gene the former condition should not represent a biosafety problem in vivo.
Follow-up by MRI and CT demonstrated a significant and sustained reduction of the tumour mass (50% of initial volume, 40 ml) with clinical benefit in patient 3. In this patient tumour reduction was still continuing at 1 month after GCV withdrawal, an effect clearly unrelated to enzyme-directed prodrug activation. A different response was noticed in patients 1 and 2 presenting areas of necrosis (2 ml volume) around the site of RVPC injection at the time of GCV administration. Thus, distinct mechanisms may account for the clinical regression observed.
As revealed by RT-PCR and in situ hybridisation in biopsied specimens, neo and tk mRNAs were present in the inoculated tumour of patient 2 in the absence of Moloney structural gene sequences. In the case of patient 3, DNA sequences of neo, gag and tk genes were detected. However, neither was vector gene expression perceived, nor was the presence of RVPC detected by immunohistochemistry. This is an indication of the persistence of tran-
Figure 4 Histological examination and in situ hybridisation. Haematoxylin-eosin staining was performed on stereotactic biopsies from patient 3 (a and b) and patient 2 (c and d). Original magnifications are ×25 (a), ×16 (b) and ×40 (c and d). Immunohistological analysis of inflammatory cells within affected tissue showed many CD3 + T lymphocytes (a and c) (a proportion expressing the activated cytotoxic phenotype as defined by expression of CD8 and Granzyme-B, not shown), together with 'young' activated macrophages as defined by the strong immunostaining with Mac387 antibody (b and d). In situ hybridization with a TK-antisense deoxygenin-conjugated riboprobe performed on biopsies from patient 2. (e) (×40) shows a positive signal in scattered cells within the tumour tissue, while f (×40) is the corresponding negative control (sense riboprobe). In (g) (×40) an intense positive signal is evident in endothelial cells. The corresponding negative control (sense riboprobe) is shown in panel (h) (×40).
scriptionally inactive RVPC genes in the lesion context at almost 2 weeks after implantation. Lack of tk transcription in the biopsied material of patient 3 could be due to sampling failure or to the presence of intense necrosis. In situ hybridisation, performed in patient 2 tumour biopsies, confirmed that the vector had travelled some distance from the site of RVPC inoculation to transduce GBM cells, although with low efficiency. Interestingly, endothelial cells were intensively stained by the tk probe, indicating that the vector had targeted the neo-vascular component, a highly replicative population in glioblastomas. This is consistent with an anti-angiogenic effect of our gene therapy that, besides direct tumour suicide, may be relevant to the clinical response. 10 This effect could further contribute to the bystander antitumour activity known to be associated with tk-GCV treatment. 2, 3, 11 Another distinct feature of the present study is the presence of large tumour infiltrates of immune-inflammatory cells, notwithstanding standard treatment with dexamethasone. 1 No signs of inflammation were noticeable in pretreatment biopsies. The observed inflammatory response has not been previously reported in other TK trials (Ram et al, 12 Ostertag and Chiocca, personal communications). Such a finding has pharmacokinetic implications. An increase of the tumour extracellular fluid, due to inflammation, would allow better access of the hydrophilic GCV molecules 13 into the compact tumour masses, amplifying the therapeutic effects of the drug. 2, 11, 14, 15 Infiltrating cells were mainly mononuclear CD4 + and CD8 + lymphocytes together with macrophages, NK cells and neutrophils, suggesting IL-2-and secondary cytokine-driven response. Previous studies in both xenogeneic and syngeneic IL-2-engineered tumour models showed that induction of tumour cell cytotoxicity by HSVtk gene transfer and ganciclovir might stimulate an immune antitumour response, with predominance of neutrophils and activated macrophages. [16] [17] [18] [19] [20] Thus, intratumour production of IL-2 combined with xenoantigen expression (murine packaging cells, HSVtk and Neo) 20 and with the expression of antigens likely associated with GBM, may potentiate specific and nonspecific immune responses leading to tumour 'rejection'. [20] [21] [22] Intracerebral production of IL-2 occurring in patient 2 after GT provides more direct evidence that this cytokine is indeed expressed from the vector and may play a local immunostimulatory role. It is noteworthy that we were not able to measure any IL-2 CSF activity in a series of normal subjects and of patients with GBM and other gliomas (unpublished data). CSF levels of IL-2, still detectable in patient 2 after GCV treatment, may derive from autocrine-paracrine secretion of recruited infiltrating immune-inflammatory cells. Such a scenario might describe the pleiotropic mechanisms accounting for the long-term clinical response of patient 3. Recently, Ram et al reported the genetic treatment of GBM by intratumoural implantation of murine packaging cells producing a retroviral vector expressing only HSVtk as the therapeutic gene. 12 Their study was limited to small tumour lesions and showed responses only in glioblastomas of 1.5 ml. In the two tumours from which samples were surgically obtained before GCV administration, there was no lymphocyte infiltration. Although the study by Ram et al and our study were both conducted with few patients, the American cases could well serve as a control for our investigation to prove the additive immune-stimulatory effect played by IL-2. As Ram et al observed by in situ hybridisation, our data, obtained both by the same technique and by RT-PCR, confirmed that limited gene transfer to tumours had occurred. In this regard, we have provided evidence on the nature of some bystander mechanisms that must be responsible for local antitumour activity. In fact, besides a potential antiangiogenic activity, an immune response was elicited by our construct, as clearly documented in vivo by the presence of IL-2 in CSF and tumour infiltration by activated macrophages and CD8
+ lymphocytes. Therefore, we share Ram's claim that means other than tk, more actively engaging the immune system, should be explored for the treatment of GBM.
In conclusion, our gene therapy pilot study provides in vivo evidence of gene transfer in glioblastoma cells and response to therapeutic genes. Results indicate that antitumour activity of this treatment may result both from the metabolic suicide of cancer and endothelial cells and from an immune-inflammatory rejection. Bystander effects elicited by tk and IL-2 could explain tumour regression, notwithstanding low transduction efficiency. Aiming at enhancing immunological effects, our therapeutic strategy should prove superior to the approach based on treatment with tk gene only, if tested on a larger scale. The limited spatial extension travelled by the vector from the site of RVPC injection and the low level of gene transfer is an indication for earlier treatment of glioblastoma recurrences. Efforts should be devoted to developing a new generation of high titre retroviral vectors, with higher transduction efficiency, suitable for direct inoculation into tumours. Expression of therapeutic gene combinations, exploiting the immune system to promote a more generalised response, should also be further investigated.
Our findings provide a new perspective on the genetic treatment of malignant brain tumours that exploit the immune system.
Materials and methods
Cell culture and vector production The PA317 packaging cell line was grown in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Paisley, UK) supplemented with 10% (v/v) heat inactivated fetal calf serum, penicillin (100 U/ml) and streptomycin (100 mg/ml). PA317 cells were transfected with the pLIL-2-TK vector and selected for G418-resistant clones. The clones were tested for vector titre and for the presence of RCR 23 and grown free of microbial contamination in a biosafety level 3 GMP facility.
Clinical protocol for in vivo gene transfer Experimental and clinical procedures of this trial were based on those already approved by RAC/FDA. 1 Positive assent was obtained from the ethical committees of the University of Padova and of the Vicenza City Hospital. Each patient gave informed consent to enter the trial. Criteria for eligibility to participate in the study were: (1) age over 18 years; (2) histological evidence of glioblastoma multiforme; (3) Karnofsky score 5 over 70; and (4) clinical and/or radiological evidence of tumour progression after completion of standard treatment (craniotomy removal plus fractionated radiotherapy). Patients were followed with virological and MRI monitoring throughout the study to assess biosafety and clinical efficacy of the gene therapy protocol.
Four GBM patients with recurrent tumours of 60-180 ml volume, were treated by stereotactic implantation of pLIL-2-TK retroviral vector producing cells (RVPC) into the tumour masses. The retroviral vector (pLIL-2-TK) ( Figure 1 ) used in this study expresses two therapeutic genes, the human interleukin-2/IL-2 and the HSVtk. pLIL-2-TK construction and pre-clinical application of a high titre clone (2.5 × 10 5 transducing units/ml of culture supernatant) have been previously reported. 8 Three patients were stereotactically injected into the tumour mass with freshly cultured 1.5-3 × 10 8 viable RVPC in 6-9 ml suspension (the maximum injectable volume at which cell viability was preserved). Releasing a small fragment of a titanium clip, which is MRI compatible and clearly identified in CT and radiographic films, marked the site of injection. Patient 4 received 3 × 10 8 RVPC by a subcutaneous reservoir connected to an indwelling catheter positioned in the surgical cavity after primary tumour removal (Table 1) . In two patients, who expressed written consent, the site of RVPC implantation was biopsied immediately before GCV treatment to ascertain transduction efficiency in vivo. Seven to 14 days after implantation the patients were treated by GCV intravenously at a dose of 5 mg/kg body weight twice daily for 14 days. [1] [2] [3] 5, 8, 23, 24 Detection of RCR and vector sequences in clinical samples Blood, urine and stool specimens were tested weekly for the presence of RCR by a conventional reverse transcriptase (RT) assay. 25 Peripheral blood mononuclear cells and cerebral biopsy tissues were analysed with direct and reverse PCR for the presence of tk, neo and gag genes and specific transcripts thereof. DNA was extracted with phenol/chloroform and RNA according to a standard procedure. 26 cDNA was synthesised from template RNA using 50 U MuLV RT (Perkin Elmer, Norwalk, CT, USA), standard buffer conditions and 0.6 m reverse primer. PCR conditions included similar denaturation (94°C for 1 min) and extension steps (72°C for 1 min) for neo, gag and tk. The annealing step (1 min) was performed at 60°C, 60°C and 53°C, respectively. All reactions were terminated by a final 10 min extension. To exclude the presence of contaminating DNA in the examined samples and to confirm competence of extracted RNA, a direct PCR for ␤-globin and a reverse PCR for ␤-actin were always run as controls. The following forward and reverse primers were utilised for neo (5′ ACT GAA GCG GGA AGG GAC TGG 3′, 5′ AGA AGC CGA TAG AAG GCG ATG 3′), gag (5′ CTT CCT AGA GAG ACT TAA GG 3′, 5′ GTT GGG ACC TCC TTC GTT CTC 3′), and tk (5′ CTG CGG GTT TAT ATA GAC GG 3′, 5′ CAT TGT TAT CTG GGC GCT 3′). Amplicons were visualised by electrophoresis in 1.5% agarose gels (Seakem LE, FMC, Rockland, ME, USA) with ethidium bromide staining. A comparative evaluation of relative intensity of the bands was conducted with a Gel Doc 1000 apparatus (Biorad, Hercules, CA, USA) for videodensitometry, interfaced with a Collage version 3.0 software (fotoDyne; Hartland, WI, USA).
Immunohistochemical analysis
The presence of the tk transcripts was also investigated in the tumour samples by an in situ hybridisation technique. Biopsies were fixed in 10% formalin and paraffin embedded. Sections, 7 m thick, were processed for in situ hybridisation with digoxigenin-labelled RNA probes. 27 A 237 bp cDNA encompassing the ATP binding site of HSV-1 tk was cloned into a pCR TM II vector (Invitrogen, Leek, The Netherlands) and transcribed with either T7 or Sp6 RNA polymerase, to yield antisense and sense RNA probes, respectively. The sense RNA probe was used as a negative control. Specimens were studied morphologically by haematoxylin-eosin staining and by immunohistochemistry 5, 28 to evaluate the cellular components of the tumour mass and the inflammatory infiltrate. The following antibodies were utilised: anti-glial fibrillary acidic protein GFAP, CD68, Mac387, CD57, CD20, CD79a, CD8, CD3, CD15 (Dako, Glostrup, Denmark), CD1 (Immunotech, Marseille, France), CD56/N-CAM (Neomarkers, Fremont, CA, USA) and Granzyme-B (Monosan, Uden, The Netherlands).
Assay of IL-2 production in cerebral spinal fluid (CSF) IL-2 concentration in CSF samples was determined by the use of a highly specific and sensitive (0.1 U/ml) immunoenzymatic assay (IL-2 EASIA Medgenix; Bouty; Milan, Italy), according to instructions provided by the manufacturer.
